Displaying 26–50 of 249 results for Paul Thomas, Senior Editor
Tectonic shifts are changing the way pharma workers will view loyalty and employment, says Kelly Services Alan Edwards.
Insights on the 2012 job market from an industry insider.
VP David Chang shares insights on strategy, as well as tech transfer best practices.
When it comes to patient safety, says Brian Johnson, there should be no competitive advantage.
Pharmaceutical machine vision technologies are getting simpler and cheaper, and yet tackling more varied applications.
We have a ways to go before any kind of equilibrium is established in the pharma workforce, the job market guru says.
CRBs Eric Unrau talks about what worked at Shire Lexington, and what limitations need to be overcome for single-use systems.
"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.
If not, maybe greed can help overcome manufacturings PR problem with young professionals.
Modular construction and disposable process equipment are maximizing agility and minimizing risk.
FDA provides more direction as questions arise about dosage consistency.
Modularly constructed facilities are becoming less expensive, and more practical, for small and large drug manufacturers alike.
Videoconferencing amongst manufacturing professionals is easing everything from tech transfer to troubleshooting.
A talk with Hydes Peter Watler about trends shaping biopharma facilities today and tomorrow.
MedImmunes approach may help take the blame off automation for plant startup delays.
While modular drug facilities have had inconsistent results to date, they are an inevitable part of pharmas future. We speak with modular construction expert Pär Almhem.
Its time to make counterfeiting less economically tantalizing.
A look at data on how the industry chooses with whom to outsource, and what it really thinks about potential partners.
When equipment and processes challenge solvent recovery for small-volume streams, an atypical approach is needed, says Pfizers Frank Urbanski.
Capable new Raman-based and other handheld technologies are proliferating as drug manufacturers see the need for quick, mobile raw materials inspection capabilities.
Communities can partner with manufacturers, but they cant apply pressure.
Pharma Tech Industries Preston Wright talks about the need to move to a consistent quality presence that is both efficient and effective.
Science-based is well and good, but FDAs guidance may create confusion.
Rapid microbiological methods continue to be developed in order to support or supplant compendial methods.